The biotech, which has a deal with Eli Lilly worth as much as $1.1 billion, is developing two targeted radiopharmaceuticals ...
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...
Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a ...
Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...
Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key ...
Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III ...
Ambros Therapeutics’ non-opioid bisphosphonate analgesic, already approved in Italy, will soon begin a pivotal test in the ...
The FDA had previously turned back the heart rhythm nasal spray twice, once in late 2023 with a refusal to file letter and ...
Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...
For $950 million upfront, Sobi will gain ownership to pozdeutinurad, an oral URAT1 inhibitor that performed well in Phase II ...
Kyverna plans to submit mivocabtagene autoleucel to the FDA for approval in the first half of 2026. If approved, it would be ...
Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine's valuation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback